Partner
NDA Partners
Daniela Drago is a Partner at NDA Partners. She has significant domestic and international expertise in the development of small molecules, biologics, cell & gene therapies, and combination products in many rare and common disease areas, including ophthalmology, neurology, and oncology. Daniela held leadership roles in the pharmaceutical and biotech industries, consulting organizations, and academic institutions. She worked for companies ranging in size from start-ups to Fortune 500, including Roche, Biogen, and Bausch & Lomb. She was formerly an Associate Professor at George Washington University’s School of Medicine, where she also directed the regulatory affairs and the clinical & translational research programs. Currently, she serves on the Board of Directors of RAPS and on the Regulatory Affairs Committee of the American Society of Gene and Cell Therapy (ASGCT). She is a fellow of RAPS (FRAPS) and of The Organisation for Professionals in Regulatory Affairs (FTOPRA). Daniela has received several awards, including the TOPRA Award for Regulatory Excellence and the RAPS Community Leadership Award. She received her Ph.D. in Chemistry from the Swiss Federal Institute of Technology (ETH Zurich, Switzerland).
Drug Development in the EU: Regulatory Standards, Supports, and New Approaches
Monday, September 16, 2024
8:30 AM – 4:00 PM PDT
RAPS BOD Roundtable: Emerging Regulatory Trends
Wednesday, September 18, 2024
10:45 AM – 11:15 AM PDT